TSXV:CNJ.P - Post by User
Comment by
SurfForWealthon Oct 30, 2003 6:50pm
![](https://assets.stockhouse.com/kentico-cms/0342-00/images/Sprite.svg#id_Post_Views_Icon)
173 Views
Post# 6583973
RE: Research Capital update on CNJ
RE: Research Capital update on CNJTD had an update today also;
Cangene has entered into an exclusive European distribution agreement with BioGeneriX to
distribute CNJ’s generic biologic product known as recombinant human growth hormone (rhGH).
Cangene has investigated its r-hGH product in children with GH deficiency and girls with
Turner Syndrome. No financial terms or anticipated regulatory filing timelines were disclosed.
BioGeneriX is a subsidiary of Ratiopharm, a leading European generic drug maker based in
Germany. This agreement with BioGeneriX highlights Cangene's continued efforts towards
furthering its generic biologics programs. Earlier in the month, CNJ filed a drug approval
application for a new drug submission with Health Canada for Leukotropin (GM-CSF).